Indivior Pharmaceuticals Inc
NASDAQ:INDVDrug Manufacturers - Specialty & Generic
+$0.26 today
- Market cap
- $4.53B
- Beta
- 1.17
- P/E (TTM)
- 19.1
- EPS (TTM)
- $2.00
Volume 3.65M
Average 2.08M
INDV Account Payables
Amounts the company owes suppliers for goods and services received.
Indivior Pharmaceuticals IncNASDAQ: INDV
Account Payables · Q2 FY2026 · quarter ended Jun 2026
Account payables falls 40.0% from a year ago
Account payables stood at $30M at the end of Q2 FY2026, down 40.0% from a year earlier and down 14.3% from the prior quarter. Over 3 fiscal years it compounded at +13.3% a year.
Context
- Account payables amounted to 2.4% of total assets at the end of Q2 FY2026, down 1.0 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -40.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 48M USD
- Year-over-year change
- -23.8%
- 4-year CAGR
- +16.6%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48M | -23.8% |
| FY2024 | 2024-12-31 | 63M | +61.5% |
| FY2023 | 2023-12-31 | 39M | +18.2% |
| FY2022 | 2022-12-31 | 33M | +26.9% |
| FY2021 | 2021-12-31 | 26M | — |
Account Payables vs competitors
How INDV compares with its peers on the latest reported figures
- INDV's Jun 2026 account payables of $30M is the 2nd highest of the 4 companies compared; the peer median is $6.83M.
- Its year-over-year change of -40.0% is the 3rd highest of 4, against a peer median of -31.9%.
- Account payables amounts to 2.4% of total assets for INDV, versus a peer median of 0.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $107.69M | +58.4% | +48.7% | 2.4% | |
INDVIndivior Pharmaceuticals Inc | Jun 2026 | $30M | -40.0% | +13.3% | 2.4% |
| Mar 2026 | $6.83M | -61.8% | +45.0% | 0.4% | |
| Jun 2026 | $5.59M | -31.9% | -36.7% | 0.4% | |
| Peer median (excluding INDV) | $6.83M | -31.9% | +45.0% | 0.4% | |
Competitors are the stored peer set for INDV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.1B | 778.18M | 316M | 319M | 195M |
| Short-term Investments | 0 | 119.64M | 94M | 1M | 0 |
| Net Receivables | 202M | 220M | 254M | 254M | 255M |
| Inventory | 95M | 114.62M | 135M | 178M | 153M |
| Other Current Assets | 27M | 18M | 444M | 34M | 15M |
| Total Current Assets | 1.44B | 1.27B | 1.27B | 839M | 652M |
| Property, Plant & Equipment (Net) | 95M | 85.46M | 124M | 139M | 170M |
| Goodwill | 0 | 0 | 0 | 2M | 0 |
| Intangible Assets | 82M | 70M | 13M | 5M | 2M |
| Long-term Investments | 0 | 98.53M | 41M | 26M | 28M |
| Tax Assets | 105M | 220.18M | 293M | 280M | 326M |
| Other Non-current Assets | 106M | 38.58M | 28M | 29M | 26M |
| Total Non-current Assets | 388M | 512.76M | 499M | 481M | 552M |
| Total Assets | 1.83B | 1.78B | 1.77B | 1.32B | 1.2B |
| Account Payables | 26M | 33M | 39M | 63M | 48M |
| Short-term Debt | 3M | 3M | 12M | 18M | 39M |
| Tax Payables | 18M | 9.05M | 17.97M | 46M | 2M |
| Deferred Revenue | 0 | 9.05M | 0 | 0 | 0 |
| Other Current Liabilities | 635M | 391M | 1.16B | 802M | 722M |
| Total Current Liabilities | 804M | 1.02B | 1.29B | 939M | 914M |
| Long-term Debt | 239M | 237M | 237M | 315M | 290M |
| Deferred Tax Liabilities | 0 | 0 | 5M | 0 | 3M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 550M | 436.78M | 390M | 381M | 73M |
| Total Non-current Liabilities | 825M | 702.78M | 666M | 728M | 388M |
| Total Liabilities | 1.63B | 1.73B | 1.96B | 1.67B | 1.3B |
| Common Stock | 70M | 68.37M | 68M | 62M | 62M |
| Retained Earnings | 1.44B | 1.31B | (295M) | (454M) | (243M) |
| Accumulated OCI | 0 | (1.34B) | (1.35B) | (46M) | (30M) |
| Other Stockholders Equity | (1.32B) | 0 | 1.3B | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 203M | 51.28M | (191M) | (348M) | (98M) |
| Total Debt | 286M | 277M | 283M | 375M | 351M |
| Net Debt | (816M) | (501.18M) | (33M) | 56M | 156M |
Indivior Pharmaceuticals Inc
NASDAQ:INDV
Intrinsic Alpha fair value
Locked
Current Price
$36.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.